Dracen Pharmaceuticals

Dracen Pharmaceuticals

Dracen Pharmaceuticals is developing cancer therapeutics by targeting glutamine metabolism with a pro-drug of a previously known glutamine analog called DON. Pro-drug allows selective intracellular release in tumors and eliminates toxic gastrointestinal effects. In addition to direct tumor effects, DON pro-drugs are able to stimulate the immune system which allows its use in combination with checkpoint inhibitors.

<< Portfolio